Overall, the researchers in this study used microfluidic devices to explore the molecular mechanisms behind LKB1−/− KRAS-driven lung cancer in-depth, and the results may lead to much-needed therapies to treat aggressive lung cancer. Here, KRAS is linked to lung cancer.